Abstract
Black and Latina transgender women (BLTW) are disproportionately impacted by HIV but remain underrepresented in HIV and health services research. Between March 2016 and May 2017, BLTW (N = 201) were recruited in Baltimore, Maryland and Washington, DC through convenience sampling for a survey assessing multilevel determinants of HIV risk and treatment outcomes. Interviews concluded with a rapid oral HIV test. Bivariate and multivariable logistic regression modeling was performed to identify gender affirmation-related correlates of self-reported HIV treatment interruptions (HIVTIs) among BLTW living with HIV who had initiated antiretroviral therapy (ART) (n = 96). Among them, 57.3% (n = 55) reported at least one HIVTI. Unmet surgical needs (aOR = 1.6), past-year marijuana use (aOR = 14.6), and no current hormone use (aOR = 24.9) were significantly (p < 0.05) associated with HIVTIs in multivariable analysis. Unmet need for gender affirmation may inhibit ART adherence, highlighting opportunities to mitigate care interruptions in alignment with community needs and goals.
Resumen
Las mujeres transgéneras negras y latinas (MTNL) son afectadas de manera desproporcionada por el VIH, pero están insuficientemente representadas en las investigaciones sobre el VIH y los servicios de salud. Entre marzo del 2016 y mayo del 2017, reclutamos MTNL (N = 201) en Baltimore, Maryland, y Washington, DC, a través de un muestreo de conveniencia para una encuesta que evaluó los determinantes de niveles múltiples del riesgo de VIH y del tratamiento del VIH. Las entrevistas concluyeron con una prueba oral rápida de VIH. Realizamos una regresión logística bivariada y multivariada para identificar los correlatos relacionados con la afirmación de género de las interrupciones del tratamiento del VIH (ITVIH) entre las MTNL que viven con el VIH que habían iniciado la terapia antirretroviral (TAR) (n = 96). Entre ellas, 57,3% (n = 55) reportaron al menos una ITVIH. Las necesidades quirúrgicas que no fueron satisfechas (aOR = 1.6), el uso de marihuana durante el año anterior (aOR = 14.6), y la falta del uso de hormonas para afirmación de género (aOR = 24.9) están significativamente asociadas (p < 0.05) con las ITVIH en el análisis multivariada. La necesidad insatisfecha de afirmación de género puede inhibir la adherencia al TAR, destacando oportunidades para mitigar las ITVIH en concordancia con las necesidades y objetivos de la comunidad transgénera.
Similar content being viewed by others
References
Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):214–22.
Poteat T, Ackerman B, Diouf D, Ceesay N, Mothopeng T, Odette K-Z, et al. HIV prevalence and behavioral and psychosocial factors among transgender women and cisgender men who have sex with men in eight African countries: a cross-sectional analysis. PLoS Med. 2017;14(11):e1002422.
Bukowski LA, Chandler CJ, Creasy SL, Matthews DD, Friedman, Stall RD. Characterizing the HIV care continuum and identifying barriers and facilitators to HIV diagnosis and viral suppression among black transgender women in the United States. J Acquir Immune Defic Syndr. 2018;79(4):413–20.
Anand T, Nitpolprasert C, Kerr SJ, Muessig KE, Promthong S, Chomchey N, et al. A qualitative study of Thai HIV-positive young men who have sex with men and transgender women demonstrates the need for eHealth interventions to optimize the HIV care continuum. AIDS Care. 2017;29(7):870–5.
Bockting WO, Miner MH, Swinburne Romine RE, Hamilton A, Coleman E. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health. 2013;103(5):943–51.
Chakrapani V, Newman PA, Shunmugam M, Dubrow R. Barriers to free antiretroviral treatment access among kothi-identified men who have sex with men and aravanis (transgender women) in Chennai. India AIDS Care. 2011;23(12):1687–94.
Glynn TR, Gamarel KE, Kahler CW, Iwamoto M, Operario D, Nemoto T. The role of gender affirmation in psychological well-being among transgender women. Psychol Sex Orientat Gend Divers. 2016;3(3):336–44.
Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12(1):1–17.
Kalichman SC, Hernandez D, Finneran S, Price D, Driver R. Transgender women and HIV-related health disparities: falling off the HIV treatment cascade. Sex Health. 2017;14(5):469–76.
Logie CH, James L, Tharao W, Loutfy MR. “We don’t exist”: a qualitative study of marginalization experienced by HIV-positive lesbian, bisexual, queer and transgender women in Toronto, Canada. J Int AIDS Soc. 2012;15(2):17392.
Poteat T, Malik M, Scheim A, Elliott A. HIV prevention among transgender populations: knowledge gaps and evidence for action. Curr HIV/AIDS Rep. 2017;14(4):141–52.
Remien RH, Bauman LJ, Mantell JE, Tsoi B, Lopez-Rios J, Chhabra R, et al. Barriers and facilitators to engagement of vulnerable populations in HIV primary care in New York City. J Acquir Immune Defic Syndr. 1999;2015(69 Suppl 1):S16–24.
Salas-Espinoza KJ, Menchaca-Diaz R, Patterson TL, Urada LA, Smith D, Strathdee SA, et al. HIV prevalence and risk behaviors in male to female (MTF) transgender persons in Tijuana. Mexico AIDS Behav. 2017;21(12):3271–8.
Sevelius JM, Saberi P, Johnson MO. Correlates of antiretroviral adherence and viral load among transgender women living with HIV. AIDS Care. 2014;26(8):976–82.
Dowshen N, Matone M, Luan X, Lee S, Belzer M, Fernandez MI, et al. Behavioral and health outcomes for HIV + young transgender women (YTW) linked to and engaged in medical care. LGBT Health. 2016;3(2):162–7.
Dowshen N, Lee S, Franklin J, Castillo M, Barg F. Access to medical and mental health services across the HIV care continuum among young transgender women: a qualitative study. Transgend Health. 2017;2(1):81–90.
Machtinger EL, Haberer JE, Wilson TC, Weiss DS. Recent trauma is associated with antiretroviral failure and HIV transmission risk behavior among HIV-positive women and female-identified transgenders. AIDS Behav. 2012;16(8):2160–70.
Mizuno Y, Beer L, Huang P, Frazier EL. Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States. LGBT Health. 2017;4(3):181–7.
Zeluf G, Dhejne C, Orre C, Mannheimer LN, Deogan C, Höijer J, et al. Targeted victimization and suicidality among trans people: a web-based survey. LGBT Health. 2018;5(3):180–90.
Magno L, Dourado I, da Silva LAV, Brignol S, Amorim L, MacCarthy S. Gender-based discrimination and unprotected receptive anal intercourse among transgender women in Brazil: a mixed methods study. PLoS ONE. 2018;13(4):e0194306.
Patel VV, Masyukova M, Sutton D, Horvath KJ. Social media use and HIV-related risk behaviors in young black and Latino gay and bi men and transgender individuals in New York City: implications for online interventions. J Urban Health. 2016;93(2):388–99.
Sevelius JM. Gender affirmation: a framework for conceptualizing risk behavior among transgender women of color. Sex Roles. 2013;68(11–12):675–89.
Chow JY, Konda KA, Borquez A, Caballero P, Silva-Santisteban A, Klausner JD, et al. Peru’s HIV care continuum among men who have sex with men and transgender women: opportunities to optimize treatment and prevention. Int J STD AIDS. 2016;27(12):1039–48.
Melendez RM, Pinto RM. HIV prevention and primary care for transgender women in a community-based clinic. J Assoc Nurses AIDS Care. 2009;20(5):387–97.
Poteat T, German D, Kerrigan D. Managing uncertainty: a grounded theory of stigma in transgender health care encounters. Soc Sci Med. 2013;84:22–9.
Prabawanti C, Dijkstra A, Riono P, Hartana G. A survey on HIV-related health-seeking behaviors among transgender individuals in Jakarta, based on the theory of planned behavior. BMC Public Health. 2015;15:1138.
Reisner SL, Perez-Brumer AG, McLean SA, Lama JR, Silva-Santisteban A, Huerta L, et al. Perceived Barriers and Facilitators to Integrating HIV prevention and treatment with cross-sex hormone therapy for transgender women in Lima, Peru. AIDS Behav. 2017;21(12):3299–311.
Sanchez NF, Sanchez JP, Danoff A. Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. Am J Public Health. 2009;99(4):713–9.
Sevelius JM, Carrico A, Johnson MO. Antiretroviral therapy adherence among transgender women living with HIV. J Assoc Nurses AIDS Care. 2010;21(3):256–64.
Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med Publ Soc Behav Med. 2014;47(1):5–16.
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2018;109(1):e1–8.
Baguso GN, Gay CL, Lee KA. Medication adherence among transgender women living with HIV. AIDS Care. 2016;28(8):976–81.
Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper GW. Characterizing the HIV prevention and care continua in a sample of transgender youth in the US. AIDS Behav. 2017;21(12):3312–27.
Jalil EM, Wilson EC, Luz PM, Velasque L, Moreira RI, Castro CV, et al. HIV testing and the care continuum among transgender women: population estimates from Rio de Janeiro, Brazil. J Int AIDS Soc. 2017;20(1):21873.
Santos G-M, Wilson EC, Rapues J, Macias O, Packer T, Raymond HF. HIV treatment cascade among transgender women in a San Francisco respondent driven sampling study. Sex Transm Infect. 2014;90(5):430–3.
Reisner SL, Biello K, Rosenberger JG, Austin SB, Haneuse S, Perez-Brumer A, et al. Using a two-step method to measure transgender identity in Latin America/the Caribbean, Portugal, and Spain. Arch Sex Behav. 2014;43(8):1503–14.
Yamanis T, Malik M, Del Río-González AM, Wirtz AL, Cooney E, Lujan M, et al. Legal immigration status is associated with depressive symptoms among Latina transgender women in Washington, DC. Int J Environ Res Public Health. 2018;15(6):1246.
Federal Poverty Level (FPL) - HealthCare.gov Glossary [Internet]. HealthCare.gov. https://www.healthcare.gov/glossary/federal-poverty-level-fpl/ (2018). Accessed 13 Dec 2018.
Straus MA, Hamby SL, Boney-McCoy S, Sugarman DB. The revised conflict tactics scales (CTS2): development and preliminary psychometric data. J Fam Issues. 1996;17(3):283–316.
Testa RJ, Habarth J, Peta J, Balsam K, Bockting W. Development of the gender minority stress and resilience measure. Psychol Sex Orientat Gend Divers. 2015;2(1):65–77.
Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–92.
Prins A, Ouimette P, Kimerling R, Cameron RP, Hugelshofer DS, Shaw-Hegwer J, et al. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Prim Care Psychiatry. 2003;9(1):9–14.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.
Akaike H. Information theory and an extension of the maximum likelihood principle. In: Parzen E, Tanabe K, Kitagawa G, editors. Selected papers of hirotugu akaike. New York: Springer; 1998. p. 199–213. https://doi.org/10.1007/978-1-4612-1694-0_15 Springer Series in Statistics.
Jr DWH, Lemeshow S, Sturdivant RX. Applied logistic regression. New Jersey: Wiley; 2013. p. 528.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, et al. Transgender women living with hiv frequently take antiretroviral therapy and/or feminizing hormone therapy differently than prescribed due to drug-drug interaction concerns. LGBT Health. 2017;4(5):371–5.
Munro L, Marshall Z, Bauer G, Hammond R, Nault C, Travers R. (Dis)integrated care: barriers to health care utilization for trans women living with HIV. J Assoc Nurses AIDS Care. 2017;28(5):708–22.
Reisner SL, Bradford J, Hopwood R, Gonzalez A, Makadon H, Todisco D, et al. Comprehensive transgender healthcare: the gender affirming clinical and public health model of fenway health. J Urban Health. 2015;92(3):584–92.
Crosby RA, Salazar LF, Hill BJ. Correlates of not using antiretroviral therapy among transwomen living with HIV: the unique role of personal competence. Transgend Health. 2018;3(1):141–6.
Grossman AH, D’augelli AR, Frank JA. Aspects of psychological resilience among transgender youth. J LGBT Youth. 2011;8(2):103–15.
Crosby RA, Salazar LF, Hill BJ. Gender affirmation and resiliency among black transgender women with and without HIV infection. Transgend Health. 2016;1(1):86–93.
Acknowledgements
We are grateful to Jean-Michel Brevelle, Falina Laron, Deborah Dunn, Ruby Corado, Alexa Rodriguez, Paty Hernandez, and Wendy Aly Escobar for their support with piloting the survey, study recruitment, and data dissemination. We are also thankful for the generous collaborative partnerships offered by the leadership and staff of Casa Ruby, Whitman Walker Health, and the DC Center. We would like to thank the people living with HIV who have generously shared their time, experiences, and bodies for the purposes of this research. Funding support was provided by the Johns Hopkins University Center for AIDS Research (P30AI094189) and the District of Columbia Center for AIDS Research (AI117970), NIH funded programs, supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. This research was also supported in part by a National Institutes of Health/National Institute for Allergy and Infectious Diseases supplement to T. Poteat (P30AI094189‐01A1). Support for this research also comes from the ADELANTE grant (AI050409) from the Centers for AIDS Research program at the National Institutes of Health to T. Yamanis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding
This publication resulted from research supported by the Johns Hopkins University Center for AIDS Research (P30AI094189) and the District of Columbia Center for AIDS Research (AI117970), NIH funded programs, supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, NIGMS, NIDDK, and OAR. This research was also supported in part by a National Institutes of Health/National Institute for Allergy and Infectious Diseases supplement to T. Poteat (P30AI094189‐01A1). Support for this research also comes from the ADELANTE grant (AI050409) from the Centers for AIDS Research program at the National Institutes of Health to T. Yamanis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Contributions
TP, ALW, MM, EEC, and TY developed data collection instruments. MM, EEC, and ML led study recruitment and data collection. CC and DH supervised study recruitment in Washington, DC and supported local data dissemination. JGR, MM, and EEC performed data analysis. JGR led writing of the draft manuscript. All authors reviewed, revised, and approved the final version of the manuscript presented for publication.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rosen, J.G., Malik, M., Cooney, E.E. et al. Antiretroviral Treatment Interruptions Among Black and Latina Transgender Women Living with HIV: Characterizing Co-occurring, Multilevel Factors Using the Gender Affirmation Framework. AIDS Behav 23, 2588–2599 (2019). https://doi.org/10.1007/s10461-019-02581-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-019-02581-x